The Chemours Company

CC • Chemicals - Specialty

$12.97

▲ +0.35 (+2.77%)

Current price

EarningsLatest report: Mar 31, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$1.95B

Growth

-0.9%

Cash Flow

4/5

Trend

Mostly stable

Evidence

Positive free cash flow · 0.34Consistent free cash flow · 4/5Healthy liquidity · 1.78High debt level · 18.34Negative growth trend

Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 5, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:36 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$12.97

Change2.77%

Shares Out150.55M

Market Cap$1.95B

Enterprise Value$5.56B

52W Range10.44 - 28.67

Beta1.39

P/E-4.75

P/S0.34

P/B9.08

P/FCF12.68

EV/Sales0.96

Price$12.97

Change2.77%

Shares Out150.55M

Market Cap$1.95B

Enterprise Value$5.56B

52W Range10.44 - 28.67

Beta1.39

P/E-4.75

P/S0.34

P/B9.08

P/FCF12.68

EV/Sales0.96

EV/EBITDA32.72

EV/FCF36.11

Earnings Yield-21.05%

FCF Yield7.89%

Dividend Yield2.77%

Gross Margin15.53%

Oper. Margin-0.09%

Profit Margin-6.65%

Debt/Eq18.34

Current Ratio1.78

Quick Ratio0.85

Revenue 5Y-0.92%

FCF 5Y-18.83%

Target$18.89

Target Upside45.64%

Target Median$18.00

Target Range14.00 - 30.00

Volume5.63M

Avg Volume2.63M

EPS Surprise0.10

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

27/100

Financial Strength

Debt, cash, stability

45/100

Growth Potential

Revenue and expansion

21/100

Price Attractiveness

Cheap or expensive today

60/100

Why this score▼

Positive free cash flow · 0.34Consistent free cash flow · 4/5Healthy liquidity · 1.78High debt level · 18.34Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

Analyst sentiment

Based on 20 analyst votes · 2026-10-21

65/100

Neutral

Bullish

Hold

Bearish

Price Target

2026-06-25

Low

$17.00

Mean

$25.75

Median

$29.50

High

$30.00

Company Overview

IPO: 6/19/2015

Industry: Chemicals - Specialty

P/B i: 9.08

Debt / Equity i: 18.34

Operating Margin: -0.09%

Net Margin: -6.65%

ROE i: -

ROIC: -

Financial Health

Score9 / 20

Debt / Equity: 18.34

Current Ratio: 1.78

Quick Ratio: 0.85

Status: Moderate

Warnings

High debt level

Insider Transactions

Recent executive and insider activity

Brokaw George R

Transaction: 05/06/2026

BUY

Change

+7,182

Price

Not reported

Filing

05/08/2026

Type

BUY

Kava Joseph Daniel

Transaction: 05/06/2026

BUY

Change

+7,182

Price

Not reported

Filing

05/08/2026

Type

BUY

Keohane Sean D

Transaction: 05/06/2026

BUY

Change

+7,182

Price

Not reported

Filing

05/08/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Brokaw George R	BUY	+7,182	Not reported	05/06/2026	05/08/2026
Kava Joseph Daniel	BUY	+7,182	Not reported	05/06/2026	05/08/2026
Keohane Sean D	BUY	+7,182	Not reported	05/06/2026	05/08/2026
SATTERTHWAITE LIVINGSTON	BUY	+7,182	Not reported	05/06/2026	05/08/2026
Kane Erin N	BUY	+7,182	Not reported	05/06/2026	05/08/2026
MATHER COURTNEY	BUY	+7,182	Not reported	05/06/2026	05/08/2026
Cowan Alister	BUY	+7,182	Not reported	05/06/2026	05/08/2026
Fletcher Pamela	BUY	+7,182	Not reported	05/06/2026	05/08/2026
Turner Leslie M	BUY	+7,182	Not reported	05/06/2026	05/08/2026
CRANSTON MARY B	BUY	+7,182	Not reported	05/06/2026	05/08/2026
MATHER COURTNEY	BUY	+1,305	Not reported	03/31/2026	04/01/2026
Will David	BUY	+8,337	Not reported	03/02/2026	03/03/2026
HOSTETTER SHANE	BUY	+47,387	Not reported	03/02/2026	03/03/2026
Martinko Joseph T.	BUY	+28,488	Not reported	03/02/2026	03/03/2026
Foley Michael Robert	BUY	+25,013	Not reported	03/02/2026	03/03/2026
Dignam Denise	BUY	+169,538	Not reported	03/02/2026	03/03/2026
Familiar Calderon Gerardo	BUY	+25,708	Not reported	03/02/2026	03/03/2026
Wellman Kristine M	BUY	+25,708	Not reported	03/02/2026	03/03/2026
Will David	SELL	-699	$18.24	03/01/2026	03/03/2026
HOSTETTER SHANE	SELL	-3,232	$18.24	03/01/2026	03/03/2026

About the Company

The Chemours Company

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The company operates through three segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. The Thermal & Specialized Solutions segment provides refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents under the Freon and Opteon brand names. The Titanium Technologies segment offers TiO2 pigment, a white pigment that delivers whiteness, brightness, opacity, durability, efficiency, and protection in applications, including architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard for use in packaging under the Ti-Pure brand name. The Advanced Performance Materials segment products portfolio includes various specialty product solutions, membranes, industrial resins, additives, films, and coatings for consumer electronics, semiconductors, digital communications, transportation, energy, oil and gas, and medical markets under the Teflon, Viton, Krytox, and Nafion brand names. It sells its products through direct and indirect channels, as well as through a network of resellers, third-party sales agents, and distributors. The Chemours Company was incorporated in 2014 and is headquartered in Wilmington, Delaware.

Source - link

Peers

APD ASH AXTA CBT ECVT ESI FF FUL IFF KWR LIN LYB OEC PPG PRM SXT TSE WLK WTTR

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

NYSE: CC: Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages CC Investors with Losses to Contact the Firm

Did you buy CC securities between February 20, 2026 and August 4, 2026? Affected CC Investor Summary Who: The Chemours Company (NYSE: CC) What: Securities fraud class action lawsuit filed Class Period: February 20, 2026 through August 4, 2026 Deadline to Seek Lead Plaintiff Status: December 7, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the reliability of the company's financial guidance Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options RADNOR, Pa.

GlobeNewsWire

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in The Chemours Company to Contact Law Firm

The Chemours Company (NYSE: CC) shareholders should email fletcher@fmoorelaw.com NEW YORK, Oct. 20, 2026 /PRNewswire/ -- What is the Investigation About? On August 4, 2026, after the market closed, Chemours announced second-quarter results and reduced its full-year adjusted EBITDA guidance from $800 million–$900 million to $775 million–$825 million.

PRNewsWire

Pomerantz Law Firm Announces the Filing of a Class Action Against The Chemours Company and Certain Officers – CC

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours " or the "Company") (NYSE: CC) and certain officers. The class action, filed in the United States District Court for the District of Delaware, and docketed under 26-cv-01299, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

GlobeNewsWire

What Does The Chemours Company's 18.63% Stock Drop Mean for Investors? The Law Offices of Howard G.

Suit alleges The Chemours Company failed to disclose key facts to investors from February 20, 2026 through August 4, 2026; lead plaintiff deadline is December 7, 2026 BENSALEM TOWNSHIP, Pa., Oct. 20, 2026 /PRNewswire/ -- The Law Offices of Howard G.

PRNewsWire

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of December 7, 2026 in The Chemours Company Lawsuit - CC

Time-Sensitive: Allegations Focus on 2026 EBITDA Guidance Representations. The lawsuit asserts that Chemours reaffirmed a full-year outlook that allegedly ignored aftermarket prebuy activity, which pulled Opteon refrigerant sales from 2026 back into 2025. Time-Sensitive: Allegations Focus on 2026 EBITDA Guidance Representations. The lawsuit asserts that Chemours reaffirmed a full-year outlook that allegedly ignored aftermarket prebuy activity, which pulled Opteon refrigerant sales from 2026 back into 2025.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-05	-0.05	0.05	0.1
2026-02-19	0.0887	0.05	-0.0387
2025-11-06	0.24	0.2	-0.04
2025-08-05	0.46	0.58	0.12
2025-05-06	0.19	0.13	-0.06
2025-02-18	0.1	0.11	0.01
2024-11-04	0.32	0.4	0.08
2024-08-01	0.57	0.38	-0.19
2024-04-30	0.18	0.32	0.14
2024-03-27	0.29	0.31	0.02
2023-10-26	0.77	0.64	-0.13
2023-07-27	1.09	1.1	0.01